ICON Public Limited (NASDAQ:ICLR) Short Interest Up 13.7% in April

ICON Public Limited (NASDAQ:ICLR - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,580,000 shares, a growth of 13.7% from the March 31st total of 1,390,000 shares. Based on an average trading volume of 540,300 shares, the short-interest ratio is presently 2.9 days. Approximately 1.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of ICON Public in the first quarter valued at approximately $31,000. Steph & Co. boosted its holdings in ICON Public by 11.2% in the 1st quarter. Steph & Co. now owns 1,852 shares of the medical research company's stock valued at $622,000 after purchasing an additional 186 shares during the period. GAMMA Investing LLC grew its position in ICON Public by 22.5% in the 1st quarter. GAMMA Investing LLC now owns 174 shares of the medical research company's stock worth $58,000 after purchasing an additional 32 shares during the last quarter. Livelsberger Financial Advisory bought a new position in shares of ICON Public during the 4th quarter worth about $29,000. Finally, State of Tennessee Treasury Department raised its position in shares of ICON Public by 4.9% during the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company's stock valued at $44,101,000 after buying an additional 7,270 shares during the last quarter. Institutional investors own 95.61% of the company's stock.

ICON Public Stock Down 1.4 %

NASDAQ ICLR traded down $4.17 during trading on Monday, reaching $304.14. The company's stock had a trading volume of 615,955 shares, compared to its average volume of 567,149. The stock has a market capitalization of $25.09 billion, a PE ratio of 37.00, a PEG ratio of 1.45 and a beta of 1.15. The business has a 50-day moving average price of $319.19 and a 200-day moving average price of $283.75. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. ICON Public has a 1-year low of $181.92 and a 1-year high of $344.77.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.13. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. The firm had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.08 billion. On average, research analysts forecast that ICON Public will post 14.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

ICLR has been the subject of a number of recent analyst reports. Evercore ISI decreased their price target on ICON Public from $350.00 to $330.00 and set an "outperform" rating for the company in a research report on Friday. Truist Financial raised their price objective on ICON Public from $357.00 to $367.00 and gave the stock a "buy" rating in a research report on Friday, February 23rd. TD Cowen upped their target price on ICON Public from $343.00 to $349.00 and gave the company a "buy" rating in a report on Friday. Mizuho reissued a "buy" rating and issued a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Finally, Robert W. Baird boosted their price objective on shares of ICON Public from $362.00 to $363.00 and gave the company an "outperform" rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, ICON Public presently has an average rating of "Moderate Buy" and a consensus price target of $327.50.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.